Adaptive Biotechnologies Corporation

ADPT

US00650F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:40:47 17/07/2024 BST			5-day change	1st Jan Change
4.365 ^USD	-1.91%		+25.29%	-10.51%

07-01	Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell 3000E Index	CI
07-01	Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell Microcap Index	CI

Adaptive Biotechnologies Corporation announced that it has received funding from Microsoft Corporation, Investment Arm

January 03, 2018

Adaptive Biotechnologies Corporation announced a private placement from new investor Microsoft Corporation, Investment Arm on January 4, 2018.

Latest news about Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell 3000E Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell Microcap Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 3000 Growth Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 2000 Growth Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 3000E Growth Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell Microcap Value Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 2500 Growth Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell 3000E Value Index	06-30	CI
Transcript : Adaptive Biotechnologies Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM	06-11
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, vs. Street Est of $38.8M	05-07	MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Transcript : Adaptive Biotechnologies Corporation, Q1 2024 Earnings Call, May 07, 2024	05-07
Adaptive Biotechnologies Corporation Announces Preliminary Unaudited Revenue Results for the First Quarter Ended March 31, 2024	04-05	CI
Adaptive Biotechnologies Corporation Announces CFO Changes	04-02	CI
Adaptive Biotechnologies Reports Preliminary Q1 Revenue, Appoints Kyle Piskel as CFO	04-02	MT
Transcript : Adaptive Biotechnologies Corporation - Special Call	04-02
Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024	04-02	CI
JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating	02-15	MT
Adaptive Biotechnologies' Q4 Loss Widens; Revenue Declines; Shares Down	02-15	MT
Transcript : Adaptive Biotechnologies Corporation, Q4 2023 Earnings Call, Feb 14, 2024	02-14
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q4 Revenue $45.8M, vs. Street Est of $48.5M	02-14	MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-14	CI
Transcript : Adaptive Biotechnologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM	01-09
Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting	12-05	CI

Chart Adaptive Biotechnologies Corporation

Duration

Period

Chart Adaptive Biotechnologies Corporation

More charts

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patientâs immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Adaptive Biotechnologies Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.45 USD

Average target price

6.333 USD

Spread / Average Target

+42.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-10.51%	656M
EXACT SCIENCES CORPORATION	-33.32%	9.17B
GUARDANT HEALTH, INC.	+19.94%	4.14B
IOVANCE BIOTHERAPEUTICS, INC.	+10.52%	2.63B
VERACYTE, INC.	-7.34%	1.95B
BGI GENOMICS CO., LTD.	-26.17%	1.85B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+41.22%	1.22B
CAREDX, INC	+52.33%	969M
SEEGENE, INC.	-6.77%	694M
CURIOX BIOSYSTEMS CO., LTD	-18.99%	235M

Bio Diagnostics & Testing